Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C

American Journal of Psychiatry

Volumn 168, Issue 10, 2011, Pages 1120-

  McKnight, Curtis ^a   Guirgis, Hossam ^a   Votolato, Nick ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HLA DQB1 ANTIGEN; QUETIAPINE; VALPROATE SEMISODIUM;

ADULT; AGRANULOCYTOSIS; CASE REPORT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HOSPITALIZATION; HUMAN; LETTER; LEUKOCYTE COUNT; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80054827294     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11020202     Document Type: Letter

References (2)

1. Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR: Candidate gene analysis identifies a polymorphism in HLA-DBQ1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011; 72:458-463
2. Dunk LR, Annan LJ, Andrews CD: Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188:255-263 (Pubitemid 43341654)